Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IXHL | PRESS-RELEASE | neutral | 4/10 | Incannex Healthcare has reactivated its share repurchase program, citing a disconnect between its current market valuati | Mar 27, 2026 |
| VOR | PRESS-RELEASE | neutral | 5/10 | Vor Biopharma announced a private placement of 5,338,078 shares at $14.05 per share, raising approximately $75 million i | Mar 27, 2026 |
| SPRY | PRESS-RELEASE | bullish | 7/10 | ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (e | Mar 27, 2026 |
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine announced the filing of a patent application in India for next-generation, non-hallucinogenic psyched | Mar 27, 2026 |
| BTAI | PRESS-RELEASE | mixed | 6/10 | BioXcel Therapeutics reported declining IGALMI revenue for Q4 and full-year 2025, with net revenue down significantly ye | Mar 27, 2026 |
| ADMA | PRESS-RELEASE | mixed | 6/10 | ADMA Biologics issued a press release refuting allegations from a short seller report that accused the company of channe | Mar 27, 2026 |
| TIL | PRESS-RELEASE | mixed | 5/10 | Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year d | Mar 27, 2026 |
| RADX | PRESS-RELEASE | neutral | 5/10 | Radiopharm Theranostics has dosed the first patient in a Phase 1 trial of RAD 402, a first-in-class radiolabeled monoclo | Mar 27, 2026 |
| GNTA | PRESS-RELEASE | bullish | 8/10 | Genenta Science (GNTA) announced a binding offer to acquire Italian aerospace and defense manufacturer Sòphia High Tech | Mar 27, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 6/10 | Zenas BioPharma announced a $200 million convertible notes offering and a $100 million equity offering (5 million shares | Mar 27, 2026 |
| DBVT | PRESS-RELEASE | neutral | 3/10 | DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document, disclo | Mar 26, 2026 |
| LONA | PRESS-RELEASE | bullish | 8/10 | LeonaBio (LONA) reported its 2025 financial results and provided updates on its strategic transformation, including the | Mar 26, 2026 |
| DBVT | PRESS-RELEASE | mixed | 6/10 | DBV Technologies reported full-year 2025 financial results, showing increased R&D spending due to pre-commercial invento | Mar 26, 2026 |
| XRTX | PRESS-RELEASE | neutral | 4/10 | XORTX Therapeutics has delayed its planned 1-for-5 share consolidation from March 27, 2026, to April 6, 2026, pending fi | Mar 26, 2026 |
| NBTX | PRESS-RELEASE | neutral | 3/10 | Nanobiotix S.A. announced it will release its fourth quarter and full-year 2025 financial results on March 31, 2026, fol | Mar 26, 2026 |
| RANI | PRESS-RELEASE | bullish | 8/10 | Rani Therapeutics reported its 2025 financial results alongside major corporate developments, including a $1.085 billion | Mar 26, 2026 |
| IMDX | PRESS-RELEASE | bullish | 8/10 | Insight Molecular Diagnostics (IMDX) reported strong revenue growth for 2025, submitted its GraftAssureDx kidney transpl | Mar 26, 2026 |
| SPRO | PRESS-RELEASE | bullish | 8/10 | Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177 | Mar 26, 2026 |
| LBRX | PRESS-RELEASE | bullish | 8/10 | LB Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by a significant reduction in annua | Mar 26, 2026 |
| RKDA | PRESS-RELEASE | mixed | 6/10 | Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% increase in Zola® cocon | Mar 26, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 5/10 | Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction in R&D and G&A expens | Mar 26, 2026 |
| SIGA | PRESS-RELEASE | neutral | 4/10 | SIGA Technologies announced a special cash dividend of $0.60 per share, consistent with the prior year's special dividen | Mar 26, 2026 |
| APGE | PRESS-RELEASE | neutral | 5/10 | Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 mill | Mar 26, 2026 |
| DARE | PRESS-RELEASE | mixed | 5/10 | Daré Bioscience reported its 2025 financial results, highlighting a significant reduction in R&D expenses due to $16.4M | Mar 26, 2026 |
| KYTX | PRESS-RELEASE | mixed | 6/10 | Kyverna Therapeutics reported financial results for Q4 and full year 2025, highlighted by strong clinical progress in it | Mar 26, 2026 |
| CANF | PRESS-RELEASE | mixed | 6/10 | Can-Fite BioPharma reported its 2025 financial results, showing a 40% year-over-year decline in revenue to $0.41 million | Mar 26, 2026 |
| MGTX | PRESS-RELEASE | mixed | 7/10 | MeiraGTx reported financial results for 2025, highlighted by a significant decline in service revenue and a net loss red | Mar 26, 2026 |
| CGTX | PRESS-RELEASE | neutral | 5/10 | Cognition Therapeutics (CGTX) reported financial results for Q4 and full year 2025, showing reduced net loss of $23.5 mi | Mar 26, 2026 |
| WVE | PRESS-RELEASE | bullish | 8/10 | Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant | Mar 26, 2026 |
| UPB | PRESS-RELEASE | mixed | 6/10 | Upstream Bio reported Q4 and full-year 2025 financial results, highlighted by a strong cash position of $341.5 million a | Mar 26, 2026 |